Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden

TI Verhoef, Ken Redekop, S Langenskiold, F Kamali, M Wadelius, G Burnside, AH Maitland-van der Zee, DA Hughes, M Pirmohamed*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

36 Citations (Scopus)
1 Downloads (Pure)

Abstract

We aimed to assess the cost-effectiveness of pharmacogenetic-guided dosing of warfarin in patients with atrial fibrillation (AF) in the United Kingdom and Sweden. Data from EU-PACT, a randomized controlled trial in newly diagnosed AF patients, were used to model the incremental costs per quality-adjusted life-year (QALY) gained by pharmacogenetic-guided warfarin dosing versus standard treatment over a lifetime horizon. Incremental lifetime costs were £26 and 382 Swedish kronor (SEK) and incremental QALYs were 0.0039 and 0.0015 in the United Kingdom and Sweden, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were £6 702 and 253 848 SEK per QALY gained. The ICER was below the willingness-to-pay threshold of £20 000 per QALY gained in 93% of the simulations in the United Kingdom and below 500 000 SEK in 67% of the simulations in Sweden. Our data suggest that pharmacogenetic-guided dosing of warfarin is a cost-effective strategy to improve outcomes of patients with AF treated with warfarin in the United Kingdom and in Sweden.
Original languageEnglish
Pages (from-to)478-484
Number of pages7
JournalPharmacogenomics Journal
Volume16
Issue number5
DOIs
Publication statusPublished - 7 Jun 2016

Research programs

  • EMC NIHES-05-63-02 Quality

Fingerprint

Dive into the research topics of 'Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden'. Together they form a unique fingerprint.

Cite this